A new special section titled "Medical Countermeasures" (MC), has been published in the latest issue of The Journal of Pharmacology and Experimental Therapeutics (JPET). Thirty-three articles showcasing experimental and translational research on MCs, specifically focus on therapeutic agents combating chemical, biological, radiological and nuclear (CBRN) threats. This special section also includes commentary articles that offer comprehensive overviews of current research and provide insight into the diverse spectrum of the MCs covered in this issue.
Featured papers highlight the latest advancements in MC research, delivering insightful outcomes on experimental models, mechanisms, and translational research for CBRN threats. Notable contributions include the development of neurosteroid and innovative anticonvulsants for nerve agent poisoning; exploration of chronic impacts and diagnostic tracers for organophosphate (OP) neurotoxicity; establishment of pioneering pediatric OP models; identification of novel molecules for ocular, pulmonary and vesicant injuries; and repurposing of existing drugs for the treatment of botulism, cyanide, Gulf war illness and nerve agent poisoning.
This research on MCs serves as a cornerstone for developing effective therapies against CBRN threats, catering to the critical needs of both military and civilian populations.
All content on “Medical Countermeasures” is available in the February 2024 (388/2) issue of The Journal of Pharmacology and Experimental Therapeutics and is freely accessible through July 2024.